The role of myelin in neurodegeneration : implications for drug targets and neuroprotection strategies
© 2023 the author(s), published by De Gruyter, Berlin/Boston..
Myelination of axons in the central nervous system offers numerous advantages, including decreased energy expenditure for signal transmission and enhanced signal speed. The myelin sheaths surrounding an axon consist of a multi-layered membrane that is formed by oligodendrocytes, while specific glycoproteins and lipids play various roles in this formation process. As beneficial as myelin can be, its dysregulation and degeneration can prove detrimental. Inflammation, oxidative stress, and changes in cellular metabolism and the extracellular matrix can lead to demyelination of these axons. These factors are hallmark characteristics of certain demyelinating diseases including multiple sclerosis. The effects of demyelination are also implicated in primary degeneration in diseases such as glaucoma and Alzheimer's disease, as well as in processes of secondary degeneration. This reveals a relationship between myelin and secondary processes of neurodegeneration, including resultant degeneration following traumatic injury and transsynaptic degeneration. The role of myelin in primary and secondary degeneration is also of interest in the exploration of strategies and targets for remyelination, including the use of anti-inflammatory molecules or nanoparticles to deliver drugs. Although the use of these methods in animal models of diseases have shown to be effective in promoting remyelination, very few clinical trials in patients have met primary end points. This may be due to shortcomings or considerations that are not met while designing a clinical trial that targets remyelination. Potential solutions include diversifying disease targets and requiring concomitant interventions to promote rehabilitation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Reviews in the neurosciences - 35(2024), 3 vom: 25. Apr., Seite 271-292 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Parrilla, Gabriella E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 24.04.2024 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1515/revneuro-2023-0081 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364749385 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364749385 | ||
| 003 | DE-627 | ||
| 005 | 20240425232513.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/revneuro-2023-0081 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM364749385 | ||
| 035 | |a (NLM)37983528 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Parrilla, Gabriella E |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of myelin in neurodegeneration |b implications for drug targets and neuroprotection strategies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 24.04.2024 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 the author(s), published by De Gruyter, Berlin/Boston. | ||
| 520 | |a Myelination of axons in the central nervous system offers numerous advantages, including decreased energy expenditure for signal transmission and enhanced signal speed. The myelin sheaths surrounding an axon consist of a multi-layered membrane that is formed by oligodendrocytes, while specific glycoproteins and lipids play various roles in this formation process. As beneficial as myelin can be, its dysregulation and degeneration can prove detrimental. Inflammation, oxidative stress, and changes in cellular metabolism and the extracellular matrix can lead to demyelination of these axons. These factors are hallmark characteristics of certain demyelinating diseases including multiple sclerosis. The effects of demyelination are also implicated in primary degeneration in diseases such as glaucoma and Alzheimer's disease, as well as in processes of secondary degeneration. This reveals a relationship between myelin and secondary processes of neurodegeneration, including resultant degeneration following traumatic injury and transsynaptic degeneration. The role of myelin in primary and secondary degeneration is also of interest in the exploration of strategies and targets for remyelination, including the use of anti-inflammatory molecules or nanoparticles to deliver drugs. Although the use of these methods in animal models of diseases have shown to be effective in promoting remyelination, very few clinical trials in patients have met primary end points. This may be due to shortcomings or considerations that are not met while designing a clinical trial that targets remyelination. Potential solutions include diversifying disease targets and requiring concomitant interventions to promote rehabilitation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a primary degeneration | |
| 650 | 4 | |a remyelination | |
| 650 | 4 | |a transsynaptic degeneration | |
| 650 | 4 | |a treatment targets | |
| 700 | 1 | |a Gupta, Vivek |e verfasserin |4 aut | |
| 700 | 1 | |a Wall, Roshana Vander |e verfasserin |4 aut | |
| 700 | 1 | |a Salkar, Akanksha |e verfasserin |4 aut | |
| 700 | 1 | |a Basavarajappa, Devaraj |e verfasserin |4 aut | |
| 700 | 1 | |a Mirzaei, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Chitranshi, Nitin |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, Stuart L |e verfasserin |4 aut | |
| 700 | 1 | |a You, Yuyi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reviews in the neurosciences |d 1987 |g 35(2024), 3 vom: 25. Apr., Seite 271-292 |w (DE-627)NLM074824201 |x 2191-0200 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2024 |g number:3 |g day:25 |g month:04 |g pages:271-292 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/revneuro-2023-0081 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2024 |e 3 |b 25 |c 04 |h 271-292 | ||